TB-500 fragment
Ac-Tβ4(17–23) · N-acetyl-LKKTETQ
This reference describes the N-acetylated thymosin beta-4 fragment Ac-LKKTETQ identified in published TB-500 analytical work. It does not establish that the Aminos TB500 listing contains that fragment.
Reviewed September 2026
- Residues
- Not established. unverified: Identity/chemical-form specification required. TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4.
- Average mass
- Not established. unverified: Identity/chemical-form specification required. TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4.
- pI
- Not established. unverified: Identity/chemical-form specification required. TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4.
Reference details
| Residues | Not established |
|---|---|
| Average mass | Not established |
| pI | Not established |
| Aliases | Ac-Tβ4(17–23), N-acetyl-LKKTETQ |
|---|---|
| Research area | Tissue |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4.
- Residues: Not established (unverified). Identity/chemical-form specification required. TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4. Residues source 1
- Average mass: Not established (unverified). Identity/chemical-form specification required. TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4. Average mass source 1
- pI: Not established (unverified). Identity/chemical-form specification required. TB-500 is an ambiguous catalogue designation. A primary analytical paper identified acetylated thymosin-beta4(17–23) in its tested sample; that does not identify this lot or justify choosing between that fragment and full thymosin-beta4. pI source 1
Reference scope and linked records
Reference type: Modified peptide; product identity unresolved.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: TB500. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
- BPC-157
- Wolverine Stack: BPC157 + TB500
- Glow Stack: BPC157 + TB500 + GHK-Cu
- Klow Stack: BPC157 + TB500 + GHK-Cu + KPV
Sources and their scope
- Esposito et al.: identification of the active content of TB-500 by high-resolution mass spectrometry. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About TB-500 fragment
Identity and context
Esposito and colleagues identified an N-terminally acetylated fragment corresponding to residues 17–23 of thymosin beta-4. The short fragment and the full 43-residue thymosin beta-4 molecule are different identities. The acetyl group also distinguishes the reported material from unmodified LKKTETQ.
Reference classification
Modified peptide; product identity unresolved. The linked catalogue product is TB500. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Request a structure-specific analytical report stating full-length peptide or fragment, sequence, N-terminal acetylation and terminal chemistry. Until that is available, neither a molecular mass nor a residue count should be assigned to the catalogue material.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | The researchers characterized a confiscated TB-500 sample, synthesized a reference peptide and developed an analytical strategy. This is strong evidence for what they found in that particular sample. It is not a survey proving that all products carrying the TB500 name contain the same molecule. | Source context |
| What cannot be inferred | The current catalogue supplies the TB500 name without a verified sequence or full chemical specification. Fragment identity therefore remains unresolved for the product and the blends that name it. No finding from full thymosin beta-4 is presented as a demonstrated effect of this fragment. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- Esposito et al.: identification of the active content of TB-500 by high-resolution mass spectrometryPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.